CD8A and neoplasm: Mechanistically, FLX475 blocks CCR4, preventing the recruitment of immunosuppressive regulatory T cells (Tregs) into the tumor and thereby reducing local immunosuppression while augmenting the activity of cytotoxic CD8+ T cells [27].